ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   


By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Telik, Inc. 

3165 Porter Drive

Palo Alto  California  94304  U.S.A.
Phone: 650-845-7700 Fax: 650-845-7800


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Discovery





 Company News
Telik, Inc. (TELK) Announces Third Quarter 2013 Financial Results 11/13/2013 9:06:24 AM    More...
Telik, Inc. (TELK) Announces Second Quarter 2013 Financial Results 8/12/2013 6:19:12 AM    More...
Telik, Inc. (TELK) Announces First Quarter 2013 Financial Results 5/13/2013 6:24:52 AM    More...
Telik, Inc. (TELK) Announces Fourth Quarter and 2012 Year End Financial Results and 2013 Financial Guidance 3/14/2013 9:52:17 AM    More...
Telik, Inc. (TELK) Announces Preliminary Agreement on Design of Phase 3 Registration Trial of Telintra® in Low to Intermediate-1 Risk Myelodysplastic Syndrome 1/23/2013 8:53:40 AM    More...
Telik, Inc. (TELK) Announces Orphan Designation of Telintra® for Treatment of Myelodysplastic Syndrome 1/14/2013 9:06:51 AM    More...
Telik, Inc. (TELK) Announces Telintra® Clinical Publication at the 54th Annual Meeting of the American Society of Hematology 12/13/2012 9:15:58 AM    More...
Telik, Inc. (TELK) Announces Third Quarter 2012 Financial Results 11/12/2012 9:27:53 AM    More...
Telik, Inc. (TELK) Announces Second Quarter 2012 Financial Results 8/13/2012 9:50:00 AM    More...
Telik, Inc. (TELK) Announces the Publication of Two Reports in the Journal of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Telintra in Patients With Myelodysplastic Syndrome 5/15/2012 10:45:39 AM    More...
12345678910...